DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0100637 A1 Brennan Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0100637 A1 Brennan Et Al US 201201 OO637A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0100637 A1 Brennan et al. (43) Pub. Date: Apr. 26, 2012 (54) GENETIC MARKERS OF SCHIZOPHRENA (60) Provisional application No. 61/100,176, filed on Sep. ENDOPHENOTYPES 25, 2008. (76) Inventors: Mark David Brennan, Publication Classification Jeffersonville, IN (US); Timothy Lynn Ramsey, Shelbyville, KY (51) Int. C. (US) GOIN 33/53 (2006.01) (52) U.S. Cl. ........................................................ 436/SO1 (21) Appl. No.: 13/344,123 (57) ABSTRACT (22) Filed: Jan. 5, 2012 This document provides methods and materials related to genetic markers of schizophrenia (SZ), Schizotypal personal Related U.S. Application Data ity disorder (SPD), and/or schizoaffective disorder (SD), (60) Division of application No. 12/612.584, filed on Nov. (collectively referred to herein as "schizophrenia spectrum 4, 2009, now Pat. No. 8,114,600, which is a continua disorders' or SSDs). For example, methods for using such tion of application No. PCT/US2009/058483, filed on genetic markers to identify an SSD (e.g., SZ) endophenotype Sep. 25, 2009. are provided. US 2012/01 OO637 A1 Apr. 26, 2012 GENETIC MARKERS OF SCHIZOPHRENA specific physiological deficits underlying disease. See Braff ENDOPHENOTYPES et al., Schiz. Bull. 33(1):21-32 (2007). SUMMARY CROSS-REFERENCE TO RELATED APPLICATIONS 0006. This disclosure provides methods of determining severity of SZendophenotypes in subjects diagnosed with SZ 0001. This application is a divisional of U.S. patent appli based on genetic variants in genes involved in a number of cation Ser. No. 12/612,584, filed on Nov. 4, 2009, which is a pathways including: glutamate signaling and metabolism, continuation of International Patent Application No. PCT/ cell adhesion, cytoskeletal architecture, vesicle formation, US2009/058483, filed Sep. 25, 2009, which claims priority to and trafficking, G-protein coupled receptors, carrier proteins U.S. Provisional Application Ser. No. 61/100,176, filed on and transporters, cell cycle modulators, neuronal develop Sep. 25, 2008, each of which are hereby incorporated by ment, calcium/calmodulin signaling, neuropeptide signaling, and several additional genes identified by virtue of their inter reference in their entirety. action with genes in high impact pathways and their expres sion in the central nervous system. This disclosure provides FEDERALLY SPONSORED RESEARCHOR methods and claims relating to determining the severity of an DEVELOPMENT SSD endophenotype according to a Subject's underlying genetic architecture. As described herein, methods for deter 0002 This invention was made with government support mining severity of an SSD endophenotype include evaluation under Grant Nos. R43MH078437, NO1 MH900001, and of SNPs for genes relating to endophenotypes in SSDs MH074027, awarded by National Institutes of Health. The including SZ, SPD, and SD. government has certain rights in the invention. 0007. In one aspect, this document features methods for determining a severity of a schizophrenia (SZ) endopheno type in a human Subject. Methods can include determining the TECHNICAL FIELD identity of an allele of at least one single nucleotide polymor phism (SNP) listed in Tables 1-3 in the subject; comparing the 0003. This document provides methods and materials identity of the allele in the subject with a reference allele, related to genetic markers of endophenotypes of Schizophre wherein the reference allele is associated with a severity of a nia (SZ), schizotypal personality disorder (SPD), and/or specific endophenotype; and determining the severity of the schizoaffective disorder (SD), (collectively referred to herein endophenotype in the Subject, based on the comparison of the as "schizophrenia spectrum disorders' or SSDs). For allele in the subject to the reference allele; thereby determin example, this document provides methods for using Such ing the severity of the Schizophrenia endophenotype in the genetic markers to identify an SSD (e.g., SZ) endophenotype Subject. in a Subject. 0008. In another aspect, this document features methods for selecting a treatment for Schizophrenia in a human Sub BACKGROUND ject. Methods can include determining the identity of an allele of at least one polymorphism listed in Tables 1-3 in the 0004. The schizophrenia spectrum disorders include subject; comparing the identity of the allele in the subject with a reference allele, wherein the reference allele is associated schizophrenia (SZ), schizotypal personality disorder (SPD), with a severity of a specific endophenotype; determining the and schizoaffective disorder (SD). Schizophrenia (SZ) is con severity of the endophenotype in the subject, based on the sidered a clinical syndrome, and is probably a constellation of comparison of the allele in the subject to the reference allele; several pathologies. Substantial heterogeneity is seen and selecting a treatment for the Subject based on the deter between cases, which is thought to reflect multiple overlap mined severity of the specific Schizophrenia endophenotype ping etiologic factors, including both genetic and environ for the subject. mental contributions. SD is characterized by the presence of 0009 ASZ endophenotype can be a quantitative trait that affective (depressive or manic) symptoms and Schizophrenic can be measured using one or more of PANSS Total compos symptoms within the same, uninterrupted episode of illness. ite score, PANSS Positive composite score, PANSS Negative SPD is characterized by a pervasive pattern of social and composite score, and PANSS General Psychopathology com interpersonal deficits marked by acute discomfort with, and posite score. A SZ endophenotype can be a quantitative trait reduced capacity for, close relationships as well as by cogni that can be measured using the PANSS Total composite score tive or perceptual distortions and eccentricities of behavior, and the polymorphism can be at position 31 of a sequence beginning by early adulthood and present in a variety of selected from the group consisting of SEQ ID NOs:417. COInteXtS. 1471, 704, 419, 1602, 1401, and 1076. A SZendophenotype 0005 Endophenotypes are quantitative, continuously dis can be a quantitative trait that can be measured using the tributed traits, symptoms or disease dimensions S typically PANSS Positive composite score and the polymorphism can assessed by laboratory-based methods or clinical observa be at position 31 of a sequence selected from the group tion. The use of endophenotypes allows complex psychiatric consisting of SEQID NOs: 1364, 1562, 534, and 1754. A SZ, illnesses like SZ to be divided into more stable, readily defin endophenotype can be a quantitative trait that can be mea able categories that are more amendable to identification of sured using the PANSS Total composite score and the poly clear genetic associations, as they are generally more reflec morphism can be at position 31 of a sequence selected from tive of specific underlying biological processes. Identifying the group consisting of SEQ ID NOs: 1504, 1401, 275, 165, the genetic basis of specific endophenotypes also facilitates and 129. A SZ endophenotype can be a quantitative trait that identification and development of new drugs that target the can be measured using the PANSS Total composite score and US 2012/01 OO637 A1 Apr. 26, 2012 the polymorphism can beat position 31 of a sequence selected or equivalent to those described herein can be used to practice from the group consisting of SEQID NOS:688, 1882, 1751, the invention, suitable methods and materials are described and 1285. below. All publications, patent applications, patents, and 0010. A schizophrenia endophenotype can include one or other references mentioned herein are incorporated by refer more of: a Positive Symptom selected from the group con ence in their entirety. In case of conflict, the present specifi sisting of P1—delusions, P2-conceptual disorganization, cation, including definitions, will control. In addition, the P3—hallucinatory behavior, P4—exitement, P5 grandios materials, methods, and examples are illustrative only and not ity, P6—suspiciousness, P7 hostility; a Negative Symptom intended to be limiting. selected from the group consisting of N1—blunted affect, 0014. The details of one or more embodiments of the N2—emotional withdrawal, N3 poor rapport, N4 pas invention are set forth in the accompanying drawings and the sive/appathetic social withdrawal, N5—difficulty in abstract description below. Other features, objects, and advantages of thinking, N6—lack of spontaneity and flow of conversation, the invention will be apparent from the description and draw N7—stereotyped thinking; or a general psychopathology ings, and from the claims. symptom selected from the group consisting of G1—Somatic concern, G2-anxiety, G3 guilt feelings, G4 tension, DETAILED DESCRIPTION G5—mannerisms and posturing, G6—depression, G7—mo tor retardation, G8 uncooperativeness, G9 unusual 0015 This document provides methods for determining thought content, G10 disorentation, G11—poor attention, severity of an endophenotype in a patient diagnosed with SZ G12—lack of judgment and insight, G13—disturbance of based on evaluation of single nucleotide polymorphisms Volition, G14 poor impulse control, G15 preoccupation, (SNPs) for genes relating to endophenotypes of SSDs includ and G16—active Social avoidance. ing Schizophrenia (SZ), Schizotypal personality disorder 0011 Determining the identity of an allele can include (SPD),
Load more

Recommended publications
  • Microsatellites As EWS/FLI Response Elements in Ewing's Sarcoma
    Microsatellites as EWS/FLI response elements in Ewing’s sarcoma Kunal Gangwal*†, Savita Sankar*†, Peter C. Hollenhorst*†, Michelle Kinsey*†, Stephen C. Haroldsen†, Atul A. Shah†, Kenneth M. Boucher*†, W. Scott Watkins‡, Lynn B. Jorde‡, Barbara J. Graves*†, and Stephen L. Lessnick*†§¶ʈ *Department of Oncological Sciences, †Huntsman Cancer Institute, ‡Department of Human Genetics, §Huntsman Cancer Institute Center for Children, and ¶Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT 84112 Edited by Robert N. Eisenman, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved May 3, 2008 (received for review February 4, 2008) The ETS gene family is frequently involved in chromosome trans- in close proximity to low affinity binding sites for other tran- locations that cause human cancer, including prostate cancer, scription factors that allow for cooperative DNA binding. leukemia, and sarcoma. However, the mechanisms by which on- Ewing’s sarcoma was the first tumor in which ETS family cogenic ETS proteins, which are DNA-binding transcription factors, members were shown to be involved in chromosomal transloca- target genes necessary for tumorigenesis is not well understood. tions and serves as a paradigm for ETS-driven cancers (10). Ewing’s sarcoma serves as a paradigm for the entire class of Ewing’s sarcoma is a highly malignant solid tumor of children ETS-associated tumors because nearly all cases harbor recurrent and young adults that usually harbors a recurrent chromosomal chromosomal translocations involving ETS genes. The most com- translocation, t(11;22)(q24;q12), that encodes the EWS/FLI mon translocation in Ewing’s sarcoma encodes the EWS/FLI onco- fusion oncoprotein (10).
    [Show full text]
  • L1 Antisense Promoter Drives Tissue-Specific Transcription Of
    Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2006, Article ID 71753, Pages 1–16 DOI 10.1155/JBB/2006/71753 Research Article L1 Antisense Promoter Drives Tissue-Specific Transcription of Human Genes Kert Matlik,¨ Kaja Redik, and Mart Speek Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, Tallinn 19086, Estonia Received 26 July 2005; Revised 11 November 2005; Accepted 16 November 2005 Transcription of transposable elements interspersed in the genome is controlled by complex interactions between their regulatory elements and host factors. However, the same regulatory elements may be occasionally used for the transcription of host genes. One such example is the human L1 retrotransposon, which contains an antisense promoter (ASP) driving transcription into adjacent genes yielding chimeric transcripts. We have characterized 49 chimeric mRNAs corresponding to sense and antisense strands of human genes. Here we show that L1 ASP is capable of functioning as an alternative promoter, giving rise to a chimeric transcript whose coding region is identical to the ORF of mRNA of the following genes: KIAA1797, CLCN5,andSLCO1A2. Furthermore, in these cases the activity of L1 ASP is tissue-specific and may expand the expression pattern of the respective gene. The activity of L1 ASP is tissue-specific also in cases where L1 ASP produces antisense RNAs complementary to COL11A1 and BOLL mRNAs. Simultaneous assessment of the activity of L1 ASPs in multiple loci revealed the presence of L1 ASP-derived transcripts in all human tissues examined. We also demonstrate that L1 ASP can act as a promoter in vivo and predict that it has a heterogeneous transcription initiation site.
    [Show full text]
  • Computational Inferences of Mutations Driving Mesenchymal Differentiation in Glioblastoma
    Computational Inferences of Mutations Driving Mesenchymal Differentiation in Glioblastoma James Chen Submitted in partial fulfillment of the requirements for the Doctor of Philosophy Degree in the Graduate School of Arts and Sciences Columbia University 2013 ! 2013 James Chen All rights reserved ABSTRACT Computational Inferences of Mutations Driving Mesenchymal Differentiation in Glioblastoma James Chen This dissertation reviews the development and implementation of integrative, systems biology methods designed to parse driver mutations from high- throughput array data derived from human patients. The analysis of vast amounts of genomic and genetic data in the context of complex human genetic diseases such as Glioblastoma is a daunting task. Mutations exist by the hundreds, if not thousands, and only an unknown handful will contribute to the disease in a significant way. The goal of this project was to develop novel computational methods to identify candidate mutations from these data that drive the molecular differentiation of glioblastoma into the mesenchymal subtype, the most aggressive, poorest-prognosis tumors associated with glioblastoma. TABLE OF CONTENTS CHAPTER 1… Introduction and Background 1 Glioblastoma and the Mesenchymal Subtype 3 Systems Biology and Master Regulators 9 Thesis Project: Genetics and Genomics 20 CHAPTER 2… TCGA Data Processing 23 CHAPTER 3… DIGGIn Part 1 – Selecting f-CNVs 33 Mutual Information 40 Application and Analysis 45 CHAPTER 4… DIGGIn Part 2 – Selecting drivers 52 CHAPTER 5… KLHL9 Manuscript 63 Methods 90 CHAPTER 5a… Revisions work-in-progress 105 CHAPTER 6… Discussion 109 APPENDICES… 132 APPEND01 – TCGA classifications 133 APPEND02 – GBM f-CNV list 136 APPEND03 – MES f-CNV candidate drivers 152 APPEND04 – Scripts 149 APPEND05 – Manuscript Figures and Legends 175 APPEND06 – Manuscript Supplemental Materials 185 i ACKNOWLEDGEMENTS I would like to thank the Califano Lab and my mentor, Andrea Califano, for their intellectual and motivational support during my stay in their lab.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptJAMA Psychiatry Author Manuscript. Author Author Manuscript manuscript; available in PMC 2015 August 03. Published in final edited form as: JAMA Psychiatry. 2014 June ; 71(6): 657–664. doi:10.1001/jamapsychiatry.2014.176. Identification of Pathways for Bipolar Disorder A Meta-analysis John I. Nurnberger Jr, MD, PhD, Daniel L. Koller, PhD, Jeesun Jung, PhD, Howard J. Edenberg, PhD, Tatiana Foroud, PhD, Ilaria Guella, PhD, Marquis P. Vawter, PhD, and John R. Kelsoe, MD for the Psychiatric Genomics Consortium Bipolar Group Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis (Nurnberger, Koller, Edenberg, Foroud); Institute of Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Nurnberger, Foroud); Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism Intramural Research Program, Bethesda, Maryland (Jung); Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis (Edenberg); Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine (Guella, Vawter); Department of Psychiatry, School of Medicine, Corresponding Author: John I. Nurnberger Jr, MD, PhD, Institute of Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, 791 Union Dr, Indianapolis, IN 46202 ([email protected]). Author Contributions: Drs Koller and Vawter had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Nurnberger, Koller, Edenberg, Vawter. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Nurnberger, Koller, Jung, Vawter.
    [Show full text]
  • Genomic Landscape of Paediatric Adrenocortical Tumours
    ARTICLE Received 5 Aug 2014 | Accepted 16 Jan 2015 | Published 6 Mar 2015 DOI: 10.1038/ncomms7302 Genomic landscape of paediatric adrenocortical tumours Emilia M. Pinto1,*, Xiang Chen2,*, John Easton2, David Finkelstein2, Zhifa Liu3, Stanley Pounds3, Carlos Rodriguez-Galindo4, Troy C. Lund5, Elaine R. Mardis6,7,8, Richard K. Wilson6,7,9, Kristy Boggs2, Donald Yergeau2, Jinjun Cheng2, Heather L. Mulder2, Jayanthi Manne2, Jesse Jenkins10, Maria J. Mastellaro11, Bonald C. Figueiredo12, Michael A. Dyer13, Alberto Pappo14, Jinghui Zhang2, James R. Downing10, Raul C. Ribeiro14,* & Gerard P. Zambetti1,* Paediatric adrenocortical carcinoma is a rare malignancy with poor prognosis. Here we analyse 37 adrenocortical tumours (ACTs) by whole-genome, whole-exome and/or transcriptome sequencing. Most cases (91%) show loss of heterozygosity (LOH) of chromosome 11p, with uniform selection against the maternal chromosome. IGF2 on chromosome 11p is overexpressed in 100% of the tumours. TP53 mutations and chromosome 17 LOH with selection against wild-type TP53 are observed in 28 ACTs (76%). Chromosomes 11p and 17 undergo copy-neutral LOH early during tumorigenesis, suggesting tumour-driver events. Additional genetic alterations include recurrent somatic mutations in ATRX and CTNNB1 and integration of human herpesvirus-6 in chromosome 11p. A dismal outcome is predicted by concomitant TP53 and ATRX mutations and associated genomic abnormalities, including massive structural variations and frequent background mutations. Collectively, these findings demonstrate the nature, timing and potential prognostic significance of key genetic alterations in paediatric ACT and outline a hypothetical model of paediatric adrenocortical tumorigenesis. 1 Department of Biochemistry, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA. 2 Department of Computational Biology and Bioinformatics, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA.
    [Show full text]
  • Combined Linkage Analysis and Exome Sequencing Identifies Novel
    Journal of Human Genetics (2013) 58, 366–377 & 2013 The Japan Society of Human Genetics All rights reserved 1434-5161/13 www.nature.com/jhg ORIGINAL ARTICLE Combined linkage analysis and exome sequencing identifies novel genes for familial goiter Junxia Yan1, Tsutomu Takahashi2, Toshihiro Ohura3, Hiroyuki Adachi2, Ikuko Takahashi2, Eishin Ogawa4, Hiroko Okuda1, Hatasu Kobayashi1, Toshiaki Hitomi1, Wanyang Liu1, Kouji H Harada1 and Akio Koizumi1 Familial goiter is a genetic disease showing heterogeneous expression. To identify causative genes, we investigated three multigenerational goiter families with an autosomal dominant inheritance pattern. We performed genome-wide linkage analysis on all the families, combined with whole-exome sequencing in two affected individuals from each family. For linkage analysis, we considered loci with logarithm of odds (LOD) scores 41.5 as candidate regions for identification of rare variants. In one of the families, we found two rare heterozygous missense variants, p.V56M in RGS12 and p.G37D in GRPEL1, which segregate with goiter and are both located within the same haplotype on 4p16. This haplotype was not observed in 150 controls. In the other two families, we identified two additional rare missense variants segregating with goiter, p.A551T in CLIC6 on 21q22.12 and p.V412A in WFS1 on 4p16. In controls, the minor allele frequency (MAF) of p.V412A in WFS1 was 0.017 while p.A551T in CLIC6 was not detected. All identified genes (RGS12, GRPEL1, CLIC6 and WFS1) show expression in the human thyroid gland, suggesting that they may play a role in thyroid gland function. Moreover, these four genes are novel with regard to their involvement in familial goiter, supporting genetic heterogeneity of this disease.
    [Show full text]
  • Rabbit Anti-Focadhesin Antibody-SL16158R
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-Focadhesin antibody SL16158R Product Name: Focadhesin Chinese Name: Focadhesin蛋白抗体 Alias: FOCAD; FOCAD_HUMAN; Focadhesin; KIAA1797. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Pig, ELISA=1:500-1000IHC-P=1:400-800IHC-F=1:400-800ICC=1:100-500IF=1:100- 500（Paraffin sections need antigen repair） Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 200kDa Cellular localization: The cell membrane Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human Focadhesin:1-100/1801 Lsotype: IgG Purification: affinitywww.sunlongbiotech.com purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. PubMed: PubMed Chromosome 9 consists of about 145 million bases and 4% of the human genome and encodes nearly 900 genes. Considered to play a role in gender determination, deletion of the distal portion of 9p can lead to development of male to female sex reversal, the Product Detail: phenotype of a female with a male X,Y genotype.
    [Show full text]
  • Supporting Information for Proteomics DOI 10.1002/Pmic.200500648
    Supporting Information for Proteomics DOI 10.1002/pmic.200500648 Fiona M. McCarthy, Amanda M. Cooksey, Nan Wang, Susan M. Bridges, G. Todd Pharr and Shane C. Burgess Modeling a whole organ using proteomics: The avian bursa of Fabricius ª 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com Supporting Text: Determining Tissue Expression Patterns for Transcription Factors. We identified 107 transcription factors (TFs) from post-hatch bursas. Since the Transfac database (1) did not contain all of these TFs, we used PubMed literature searches to determine expression patterns for each. For each transcription factor, we searched PubMed for a combination of the protein and gene names, as determined by both NCBI and UniProt records. For example, Pax7 (gi:2576239; UniProt O42349) was searched as both PAX7 and Pax-7. In each case, articles were manually searched to confirm TF expression. We combined the TF names with the following terms to obtain reported tissue expression patterns: 1. Expression in the bursa. AND bursa* OR DT40 eg. (Pax7 OR “Pax-7”) AND (bursa* OR DT40) returned no items. 2. Expression in immune tissue. AND lymphocyte* OR leukocyte* OR “bone marrow” OR spleen OR “embryonic liver” OR hematopoietic eg. (Pax7 OR “Pax-7”) AND (lymphocyte* OR leukocyte* OR “bone marrow” OR spleen OR “embryonic liver” OR hematopoietic) returned 17 articles. 3. Expression during development. AND development OR embryo* eg. (Pax7 OR “Pax-7”) AND (development OR embryo*) returned 135 articles. 4. Expression in nervous tissue. AND neuron* OR nervous OR CNS OR retina* 1 eg. (Pax7 OR “Pax-7”) AND (neuron* OR nervous OR CNS OR retina*) returned 53 articles.
    [Show full text]
  • Genome-Wide Analysis of Genetic Alterations in Barrett's
    Laboratory Investigation (2009) 89, 385–397 & 2009 USCAP, Inc All rights reserved 0023-6837/09 $32.00 Genome-wide analysis of genetic alterations in Barrett’s adenocarcinoma using single nucleotide polymorphism arrays Thorsten Wiech1,5, Elisabeth Nikolopoulos1,5, Roland Weis1, Rupert Langer2, Kilian Bartholome´3, Jens Timmer3, Axel K Walch4, Heinz Ho¨fler2 and Martin Werner1 We performed genome-wide analysis of copy-number changes and loss of heterozygosity (LOH) in Barrett’s esophageal adenocarcinoma by single nucleotide polymorphism (SNP) microarrays to identify associated genomic alterations. DNA from 27 esophageal adenocarcinomas and 14 matching normal tissues was subjected to SNP microarrays. The data were analyzed using dChipSNP software. Copy-number changes occurring in at least 25% of the cases and LOH occurring in at least 19% were regarded as relevant changes. As a validation, fluorescence in situ hybridization (FISH) of 8q24.21 (CMYC) and 8p23.1 (SOX7) was performed. Previously described genomic alterations in esophageal adenocarcinomas could be confirmed by SNP microarrays, such as amplification on 8q (CMYC, confirmed by FISH) and 20q13 or deletion/LOH on 3p (FHIT) and 9p (CDKN2A). Moreover, frequent gains were detected on 2p23.3, 7q11.22, 13q31.1, 14q32.31, 17q23.2 and 20q13.2 harboring several novel candidate genes. The highest copy numbers were seen on 8p23.1, the location of SOX7, which could be demonstrated to be involved in amplification by FISH. A nuclear overexpression of the transcription factor SOX7 could be detected by immunohistochemistry in two amplified tumors. Copy-number losses were seen on 18q21.32 and 20p11.21, harboring interesting candidate genes, such as CDH20 and CST4.
    [Show full text]
  • A Genome-Wide Scan of Cleft Lip Triads Identifies Parent
    F1000Research 2019, 8:960 Last updated: 03 AUG 2021 RESEARCH ARTICLE A genome-wide scan of cleft lip triads identifies parent- of-origin interaction effects between ANK3 and maternal smoking, and between ARHGEF10 and alcohol consumption [version 2; peer review: 2 approved] Øystein Ariansen Haaland 1, Julia Romanowska1,2, Miriam Gjerdevik1,3, Rolv Terje Lie1,4, Håkon Kristian Gjessing 1,4, Astanand Jugessur1,3,4 1Department of Global Public Health and Primary Care, University of Bergen, Bergen, N-5020, Norway 2Computational Biology Unit, University of Bergen, Bergen, N-5020, Norway 3Department of Genetics and Bioinformatics, Norwegian Institute of Public Health, Skøyen, Oslo, Skøyen, N-0213, Norway 4Centre for Fertility and Health (CeFH), Norwegian Institute of Public Health, Skøyen, Oslo, N-0213, Norway v2 First published: 24 Jun 2019, 8:960 Open Peer Review https://doi.org/10.12688/f1000research.19571.1 Latest published: 19 Jul 2019, 8:960 https://doi.org/10.12688/f1000research.19571.2 Reviewer Status Invited Reviewers Abstract Background: Although both genetic and environmental factors have 1 2 been reported to influence the risk of isolated cleft lip with or without cleft palate (CL/P), the exact mechanisms behind CL/P are still largely version 2 unaccounted for. We recently developed new methods to identify (revision) report parent-of-origin (PoO) interactions with environmental exposures 19 Jul 2019 (PoOxE) and now apply them to data from a genome-wide association study (GWAS) of families with children born with isolated CL/P. version 1 Methods: Genotypes from 1594 complete triads and 314 dyads (1908 24 Jun 2019 report report nuclear families in total) with CL/P were available for the current analyses.
    [Show full text]
  • Genetic Variation and Functional Analysis of the Cardiomedin Gene
    TECHNISCHE UNIVERSITÄT MÜNCHEN LEHRSTUHL FÜR EXPERIMENTELLE GENETIK Genetic Variation and Functional Analysis of the Cardiomedin Gene Zasie Susanne Schäfer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzende: Univ.-Prof. A. Schnieke, Ph.D. Prüfer der Dissertation: 1. apl. Prof. Dr. J. Adamski 2. Univ.-Prof. Dr. Dr. H.-R. Fries 3. Univ.-Prof. Dr. Th. Meitinger Die Dissertation wurde am. 31.05.2011 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 02.04.2012 angenommen. Table of Contents Table of contents Abbreviations ........................................................................................................................ 7 1. Summary ..........................................................................................................................10 Zusammenfassung ...............................................................................................................11 2. Introduction ......................................................................................................................12 2.1 Genome-wide association studies (GWAS) and post-GWAS functional genomics ......12 2.2 Genetic influences on cardiac repolarization and sudden cardiac death syndrome in GWAS and the chromosome
    [Show full text]
  • International Genome-Wide Association Study Consortium Identifies Novel Loci Associated with Blood Pressure in Children and Adolescents
    Original Article International Genome-Wide Association Study Consortium Identifies Novel Loci Associated With Blood Pressure in Children and Adolescents Priyakumari Ganesh Parmar, PhD; H. Rob Taal, MD, PhD; Nicholas J. Timpson, PhD; Elisabeth Thiering, PhD*; Terho Lehtimäki, MD, PhD*; Marcella Marinelli, PhD*; Penelope A. Lind, PhD*; Laura D. Howe, PhD; Germaine Verwoert, PhD; Ville Aalto, MSc; Andre G. Uitterlinden, PhD; Laurent Briollais, PhD; Dave M. Evans, PhD; Margie J. Wright, PhD; John P. Newnham, MD; John B. Whitfield, PhD; Leo-Pekka Lyytikäinen, MD; Fernando Rivadeneira, MD, PhD; Dorrett I. Boomsma, PhD; Jorma Viikari, MD, PhD; Matthew W. Gillman, MD, SM; Beate St Pourcain, PhD; Jouke-Jan Hottenga, PhD; Grant W. Montgomery, PhD; Albert Hofman, MD, PhD; Mika Kähönen, MD, PhD; Nicholas G. Martin, PhD; Martin D. Tobin, PhD; Ollie Raitakari, MD, PhD; Jesus Vioque, MD, PhD; Vincent W.V. Jaddoe, MD, PhD; Marjo-Riita Jarvelin, MD, PhD; Lawrence J. Beilin, MD; Joachim Heinrich, PhD; Cornelia M. van Duijn, PhD; Craig E. Pennell, MD, PhD; Debbie A. Lawlor, MD, PhD†; Lyle J. Palmer, PhD†; Early Genetics and Lifecourse Epidemiology Consortium Background—Our aim was to identify genetic variants associated with blood pressure (BP) in childhood and adolescence. Methods and Results—Genome-wide association study data from participating European ancestry cohorts of the Early Genetics and Lifecourse Epidemiology (EAGLE) Consortium was meta-analyzed across 3 epochs; prepuberty (4–7 years), puberty (8–12 years), and postpuberty (13–20 years). Two novel loci were identified as having genome-wide associations with systolic BP across specific age epochs: rs1563894 (ITGA11, located in active H3K27Ac mark and transcription factor chromatin immunoprecipitation and 5′-C-phosphate-G-3′ methylation site) during prepuberty (P=2.86×10–8) and rs872256 during puberty (P=8.67×10–9).
    [Show full text]